Endocrinology Center of Excellence

Supporting patients living with a rare endocrinology condition

Orsini’s Endocrinology Center of Excellence launched in 2015 with our first pediatric growth hormone program. Today we support multiple endocrinology programs across several rare conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Endocrinology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Home Health Nursing

Access nationwide nursing support for in-home treatment or self-administration training. Our nurses provide clinical support to help patients achieve their treatment goals.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Endocrinology Conditions Supported

Explore the rare endocrinology conditions Orsini supports below.

About Tumor-induced Osteomalacia (TIO)

Tumor-induced osteomalacia is a rare paraneoplastic syndrome characterized by weakened bones due to phosphate wasting. Tumors produce a hormone-like substance causing renal phosphate loss, leading to bone softening, fractures, and muscle weakness. Diagnosis involves identifying the tumor through imaging and blood tests.

TIO Therapies Supported

Full Name	Crysvita® (burosumab-twza)
Drug	Crysvita
Manufacturer	Kyowa Kirin North America
Route of Administration	Subcutaneous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older
Disease	Tumor-induced Osteomalacia (TIO); X-linked Hypophosphatemia (XLH)
Therapeutic Area	Endocrinology & Bone Specialty
Enrollment Form Link	Enrollment Form
Phone Number	800-240-7614
Fax Number	877-793-4897
Product Website	crysvitahcp.com

About Type 1 Diabetes (T1D)

Type 1 diabetes is a chronic condition where the immune system mistakenly attacks and destroys insulin-producing cells in the pancreas. This results in insufficient insulin, leading to high blood sugar levels. Symptoms include increased thirst, frequent urination, and weight loss.

T1D Therapies Supported

Full Name	Tzield® (teplizumab-mzwv)
Drug	Tzield
Manufacturer	Sanofi
Route of Administration	Intravenous
Site of Care	Home or Healthcare Facility
Approved Indication	Delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D
Disease	Type 1 Diabetes (T1D)
Therapeutic Area	Endocrinology & Bone Specialty
Enrollment Form Link	Tzield Enrollment Form
Phone Number	800-670-5321
Fax Number	877-655-4364
Product Website	tzield.com

About X-linked Hypophosphatemia (XLH)

X-linked hypophosphatemia is a genetic disorder causing low levels of phosphate in the blood. It results from mutations in the PHEX gene, affecting phosphate reabsorption in the kidneys. XLH leads to weakened bones, bowed legs, and dental issues.

XLH Therapies Supported

Full Name	Crysvita® (burosumab-twza)
Drug	Crysvita
Manufacturer	Kyowa Kirin North America
Route of Administration	Subcutaneous
Site of Care	Home or Healthcare Facility
Approved Indication	The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older
Disease	Tumor-induced Osteomalacia (TIO); X-linked Hypophosphatemia (XLH)
Therapeutic Area	Endocrinology & Bone Specialty
Enrollment Form Link	Enrollment Form
Phone Number	800-240-7614
Fax Number	877-793-4897
Product Website	crysvitahcp.com